Literature DB >> 16627930

Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation.

Cheng-Xin Gong1, Fei Liu, Inge Grundke-Iqbal, Khalid Iqbal.   

Abstract

Neurofibrillary degeneration characterized by abnormal hyperphosphorylation and aggregation of tau in affected neurons is directly associated with dementia symptoms and plays a pivotal role in the pathogenesis of Alzheimer disease (AD) and related tauopathies. It is well established that brain glucose uptake/metabolism is impaired in AD, but how this impairment contributes to the disease is unknown. We recently found that tau in human brain is also modified by O-GlcNAcylation in addition to phosphorylation and that the former negatively regulates the latter. On the basis of these findings, we propose a novel hypothesis that the impaired glucose uptake/metabolism contributes to AD by facilitating abnormal hyperphosphorylation of tau. Further studies of this mechanism are likely to offer a novel therapeutic target for preventing and treating AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627930     DOI: 10.3233/jad-2006-9101

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  47 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Diverse regulation of AKT and GSK-3β by O-GlcNAcylation in various types of cells.

Authors:  Jianhua Shi; Shiliang Wu; Chun-ling Dai; Yi Li; Inge Grundke-Iqbal; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  FEBS Lett       Date:  2012-06-08       Impact factor: 4.124

3.  Genetic association of SLC2A14 polymorphism with Alzheimer's disease in a Han Chinese population.

Authors:  Wei Wang; Jin-Tai Yu; Wei Zhang; Wei-Zhen Cui; Zhong-Chen Wu; Qun Zhang; Lan Tan
Journal:  J Mol Neurosci       Date:  2012-03-16       Impact factor: 3.444

Review 4.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

5.  Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice.

Authors:  Yang Yu; Xiaojing Li; Julie Blanchard; Yi Li; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  J Neural Transm (Vienna)       Date:  2014-08-13       Impact factor: 3.575

6.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

Review 7.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 8.  Deregulation of brain insulin signaling in Alzheimer's disease.

Authors:  Yanxing Chen; Yanqiu Deng; Baorong Zhang; Cheng-Xin Gong
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

9.  Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria.

Authors:  Estela Area-Gomez; Ad J C de Groof; Istvan Boldogh; Thomas D Bird; Gary E Gibson; Carla M Koehler; Wai Haung Yu; Karen E Duff; Michael P Yaffe; Liza A Pon; Eric A Schon
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.